LY3022856 / Eli Lilly  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
LY3022856 / Eli Lilly
NCT01288989: A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors

Completed
1
44
US
IMC-3C5, LY3022856
Eli Lilly and Company
Neoplasms
07/14
07/14

Download Options